Enasidenib is a drug used to treat relapsed or refractoryﾠacute myeloid leukemiaﾠin people with specific mutations of theﾠisocitrate dehydrogenase 2ﾠ(IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test LPI (LP Information)' newest research report, the ﾓEnasidenib Industry Forecastﾔ looks at past sales and reviews total world Enasidenib sales in 2022, providing a comprehensive analysis by region and market sector of projected Enasidenib sales for 2023 through 2029. With Enasidenib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Enasidenib industry. This Insight Report provides a comprehensive analysis of the global Enasidenib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Enasidenib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Enasidenib market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Enasidenib and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Enasidenib. The global Enasidenib market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029. United States market for Enasidenib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. China market for Enasidenib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Europe market for Enasidenib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Global key Enasidenib players cover Celgene Corporation. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022. This report presents a comprehensive overview, market shares, and growth opportunities of Enasidenib market by product type, application, key manufacturers and key regions and countries. Market Segmentation: Segmentation by type 50mg 100mg Segmentation by application Hospital Pharmacy This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Celgene Corporation Key Questions Addressed in this Report What is the 10-year outlook for the global Enasidenib market? What factors are driving Enasidenib market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Enasidenib market opportunities vary by end market size? How does Enasidenib break out type, application? What are the influences of COVID-19 and Russia-Ukraine war?
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Enasidenib Annual Sales 2018-2029 2.1.2 World Curre
